Phenelzine Interactions

Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOI or within 14 days of stopping MAOI.

Source: NLP:desvenlafaxine

Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOIs intended to treat psychiatric disorders or within 14 days of stopping MAOI.

Source: NLP:desvenlafaxine er

Concomitant use increases risk of serotonin syndrome. Contraindicated with MAOI intended to treat psychiatric disorders or within 7 days of stopping desvenlafaxine.

Source: NLP:desvenlafaxine succinate

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure.

Source: NLP:dexmethylphenidate hydrochloride

MAOI that potentiates amphetamine effects; concomitant use can cause hypertensive crisis with potentially fatal outcomes including stroke, MI, aortic dissection.

Source: NLP:dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate

MAOI concomitant use can cause hypertensive crisis with potentially fatal outcomes including stroke, myocardial infarction, and aortic dissection. Do not use concurrently or within 14 days after discontinuing.

Source: NLP:dextroamphetamine sulfate

Not recommended for patients taking MAOIs or within 14 days of stopping. May manifest as serotonin syndrome or opioid toxicity.

Source: NLP:hydromorphone hydrochloride

MAOI that increases risk of serotonin syndrome when used with levomilnacipran. Contraindicated use.

Source: NLP:levomilnacipran hydrochloride

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, and other serious complications.

Source: NLP:methylphenidate hydrochloride

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, and renal failure.

Source: NLP:methylphenidate hydrochloride extended release

Concomitant use increases risk of serotonin syndrome. Mirtazapine is contraindicated in patients taking MAOIs.

Source: NLP:mirtazapine

Do not use morphine in patients taking MAOIs or within 14 days of stopping treatment; may cause serotonin syndrome or opioid toxicity.

Source: NLP:morphine sulfate

MAOI that increases risk of serotonin syndrome when combined with paroxetine. Paroxetine is contraindicated.

Source: NLP:paroxetine

Concomitant use of SSRIs including paroxetine and MAOIs increases the risk of serotonin syndrome.

Source: NLP:paroxetine hydrochloride

Concomitant use increases risk of serotonin syndrome.

Source: NLP:paroxetine hydrochloride hemihydrate

Concomitant use increases risk of serotonin syndrome. Sertraline is contraindicated in patients taking MAOIs.

Source: NLP:sertraline

Concomitant use of MAOI phenelzine with sertraline hydrochloride increases risk of serotonin syndrome.

Source: NLP:sertraline hydrochloride

MAOI interaction may cause serotonin syndrome or opioid toxicity. Do not use or within 14 days of stopping.

Source: NLP:tapentadol hydrochloride

Concomitant use increases risk of serotonin syndrome. Trazodone is contraindicated in patients taking MAOIs.

Source: NLP:trazodone hydrochloride

Concomitant use with MAOIs increases risk of serotonin syndrome. Contraindicated with MAOI or within 14 days of stopping MAOI.

Source: NLP:vortioxetine

Inhibition of MAO prolongs and potentiates dopamine effects, potentially resulting in severe hypertension and cardiac arrhythmia.

Source: NLP:dopamine hydrochloride

MAOI interaction may manifest as serotonin syndrome.

Source: NLP:nalbuphine hydrochloride